Myopia Control Optical Devices Patents: Leaders & Trends 2026
- 37.4% concentration at the top. The five leading assignees hold 130 of 348 records in scope, and the leader alone accounts for 45 — a field with a clear head but a long tail of single- and few-filing entrants below tenth place.
- Filing cooled from its 2021 peak. Filings ran from 38 in 2021 to 27 in 2024, a -29% pullback over that three-year span, even as the field's cumulative footprint keeps growing.
- Lens hardware dominates; software is a minority branch. G02C spectacles-and-lens claims cover 87.4% of the 348 records, while G06F digital-processing claims sit at just 7.8% — most of the documented control strategy is still optical, not computational.
Filing growth compares 2021 (38 records) with 2024 (27) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 348 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Myopia control optical devices span contact and spectacle lenses that manage peripheral defocus, orthokeratology lenses that achieve corneal reshaping, and related claims around treatment zone geometry, wearer compliance, and the rebound effect seen after lens removal. The 348 records in scope span filings from 2015 through the 2026 data cut-off, drawn from a search built on these specific technical terms rather than a broad ophthalmic category.
Because publication lags filing by roughly 18 months, the most recent one to two years in any trend understate real filing activity — 2024 is the last year that can be read as a complete picture, not 2025 or 2026.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 348 records: how filing volume has moved year over year, and which IPC subclasses carry the claims.
Filing trend: rise to a 2021 peak, then pullback
Annual filings rose from 13 in 2017 to a peak of 38 in 2021, then fell to 27 by 2024 — a -29% change over that span. 2025 and 2026 figures are still filling in due to publication lag and should not be read as a continued decline.
Technology composition by IPC subclass
G02C (spectacles and lenses) appears in 87.4% of the 348 records, confirming that lens-form hardware is the dominant claim category. A61F (implants and prostheses) follows at 27.6%, then G02B (optical elements and systems) at 11.2% and A61B (diagnosis and surgery) at 10.1%. Software-adjacent G06F claims sit at only 7.8%, and pharmacological A61K/A61P claims are each under 7%. A record can carry more than one class, so these shares add up to more than 100%.
Shares are the percentage of the 348 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Myopia Control Optical Devices with Eureka
This page is one run against one query. Ask Eureka your own question about myopia control optical devices and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited prior art
Myopia control lens with aspheric surface to create peripheral defocus
A myopia control lens with aspheric surface to create peripheral defocus onto various regions of a retina is disclosed. This lens includes a central optical zone and various asymmetrical peripheral optical zones surrounding it, each creating different amounts of blur in front of different retinal areas — a defocusing strategy intended to provide a controlled amount of myopic blur.Filed by Brighten Optix Corp, published 2019-05-23.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6010219A | Fenestrated contact lens for treating myopia | 161 |
| 2 | US20090171305A1 | Combination therapy for long-lasting ckr | 150 |
| 3 | US5270051A | Enzyme-orthokeratology | 99 |
| 4 | US20090303442A1 | Corneal and epithelial remodelling | 92 |
| 5 | US5626865A | Enzyme-orthokeratology | 85 |
| 6 | US20060152673A1 | Corneal-scleral orthokeratology contact lens | 84 |
| 7 | US20130182215A1 | Multi-focal optical lenses | 82 |
| 8 | US8201941B2 | Corneal and epithelial remodelling | 73 |
| 9 | US20120320334A1 | Corneal remodelling contact lenses and methods of treating refractive error using corneal remodelling | 70 |
| 10 | WO2013101793A1 | Multi-focal optical lenses | 62 |
Citation counts favour older records in a searched corpus and should be read as a signal of influence, not of current technical importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing strategy
Three findings that shape where a new filing is likely to land relative to existing claim density.
A clear head, then a long tail
The five leading assignees hold 130 of the 348 records in scope, with the leader alone at 45. Below tenth place (14 records), the ranking spreads thin across many single- and few-filing entrants, suggesting most incremental filing opportunity sits outside the established leaders.
Past-peak, not necessarily past-relevant
Filings peaked at 38 in 2021 and eased to 27 by 2024. That pullback describes filing volume, not technology maturity — high density in the peak years means claim space around defocus and treatment-zone geometry is already occupied, which raises the bar for a freedom-to-operate check before filing similar claims.
Optical claims dominate; digital control is thin
Lens-form hardware (G02C) covers the large majority of records, while digital-processing claims (G06F) — covering things like software-driven fitting or monitoring — sit under 8%. That gap points to a technology mix still centred on optics rather than data-driven compliance tools.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to myopia control optical devices, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Brighten Optix Corp. | WU RICHARD I TSUNG | 2 |
| Brien Holden Vision Institute | SMITH EARL LEO III | 1 |
| Brien Holden Vision Institute | SANKARIDURG PADMAJA RAJAGOPAL | 1 |
| Brien Holden Vision Institute | LAZON PERCY FABIAN | 1 |
| Brien Holden Vision Institute | HOLDEN BRIEN ANTHONY | 1 |
| Brien Holden Vision Institute | HO ARTHUR | 1 |
| Brien Holden Vision Institute | CONRAD FABIAN | 1 |
| Brien Holden Vision Institute | CHEN XIANG | 1 |
Only 10 co-assignee pairs appear across the dataset, and the strongest pairing links a single company to a named inventor rather than a joint-venture structure — most filings here are made by a single assignee acting alone.
Who is filing, and where the gaps sit
The ranked leaders concentrate a substantial share of filings, but the technology composition points to sub-areas still open to new entrants.
A single company well ahead of the field
The top-ranked assignee holds 45 of the 348 records in scope, well clear of fifth place at 18 and tenth place at 14. That gap suggests an early, sustained filing programme rather than a recent surge.
A tight mid-tier, then a long tail
Between fifth and tenth place the record counts move from 18 down to 14 — a relatively tight band — before the ranking spreads across many smaller filers. Watching this mid-tier is often more informative than watching the leader, since it is where new challengers first show up.
Recent-year activity has gone quiet across named leaders
Several of the assignees tracked for recent-year momentum show zero filings in the latest year, including year-over-year drops of -100% for at least two of them. Given the 18-month publication lag, this likely reflects filing-to-publication delay more than an actual halt in R&D.
| Assignee | Recent year | YoY |
|---|---|---|
| Brien Holden Vision Institute | 0 | -100% |
| Shamir Optical Industry Ltd. | 0 | — |
| CooperVision International Ltd. | 0 | -100% |
| Paragon CRT Co. | 0 | — |
| Eyebright Medical Technology (Beijing) Co., Ltd. | 0 | — |
| Brighten Optix Corp. | 0 | — |
| ISTA Pharmaceuticals, Inc. | 0 | — |
| Essillor International (Compagnie Generale d'Optique) | 0 | -100% |
Where to take this from here
The dataset points to specific questions worth running against your own portfolio before deciding where to file.
Check freedom-to-operate against the top 10
With 58.9% of all 348 records held by the top 10 assignees, any new filing in the G02C lens-hardware branch should be checked against their claim scope before drafting.
Run a freedom-to-operate search in EurekaMap the under-claimed branches
G06F, A61N and A61P classes carry far fewer records than G02C, which may mean genuine white space or simply that those approaches remain unproven — either way, the gap is worth mapping claim-by-claim.
Explore white space in EurekaTrack momentum, not just totals
Several leaders show zero filings in the latest tracked year; watching whether that reverses over the next publication cycle will show whether the field is genuinely cooling or just catching up on lag.
Set up monitoring in EurekaCommon questions about myopia control optical device patents
One assignee leads the ranked field with 45 of the 348 records in scope, well ahead of fifth place at 18 and tenth place at 14. The top five assignees combined hold 130 records, or 37.4% of all records in scope, and the top ten hold 58.9%. Below that, the ranking spreads across a long tail of smaller filers, so a single company's dominance does not mean the field is closed to new entrants.
Filing activity peaked in 2021 at 38 records and had eased to 27 by 2024, a -29% change over that span. That is the last year that can be read as complete, because publication lags filing by roughly 18 months, so 2025 and 2026 figures are still filling in and should not be read as evidence of a continued decline. The honest read is a cooling from peak, not a collapse.
Spectacles-and-lens claims under IPC class G02C appear in 87.4% of the 348 records, making lens-form hardware by far the largest category. Implants and prostheses (A61F) follow at 27.6%, and optical elements and systems (G02B) at 11.2%. Software-adjacent digital processing (G06F) and pharmacological classes (A61K, A61P) each sit under 8%, indicating that most documented control strategies remain optical rather than data-driven or drug-based.
The technology composition points to lighter claim density in digital compliance monitoring, electrotherapy-based defocus approaches, and pharmacological adjuncts to lens therapy — all sit well below the 87.4% coverage of core lens-hardware claims. These lighter branches may reflect genuine unclaimed opportunity or simply less mature approaches, so each should be checked individually against recent filings rather than assumed to be open. Co-assignee collaboration is also rare in this dataset, with only 10 pairs recorded, suggesting most white-space work would be pursued solo rather than through a joint filing.
US20190155055A1, assigned to Brighten Optix Corp, claims a myopia control lens with an aspheric surface built from a central optical zone and multiple asymmetrical peripheral zones that create varying amounts of peripheral blur to defocus light in front of different retinal regions. It sits squarely in the G02C lens-hardware branch that covers 87.4% of records in this dataset, so any new lens design using multi-zone asymmetric aspheric surfaces for peripheral defocus should be checked against its specific claim language. Whether it blocks a given design depends on the exact zone geometry and blur-distribution method, which requires a claim-by-claim comparison rather than a landscape-level read.
Research Myopia Control Optical Devices in depth with Eureka
Go past this page: query the whole myopia control optical devices corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.